Designed as a comprehensive course, this annual conference provided participants with the fundamental knowledge and resources, as well as the associated barriers and challenges on creating new drugs to treat and prevent neurodegenerative disease. The meeting attracted approximately 135 leading academic, industry and government scientists from around the world. The ADDF developed this conference in collaboration with the National Institutes of Health (NIH).